NCT05004324UnknownPhase 3
A Two-stage, Multi-center, Randomized, Double-Blind, Placebo Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
Kang Stem Biotech Co., Ltd.1 site in 1 country308 target enrollmentStarted: June 29, 2021Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Enrollment
- 308
- Locations
- 1
- Primary Endpoint
- EASI(Eczema Area and Severity Index)-50
Study Overview
Brief Summary
This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults aged 19 years and older at time of informed consent
- •Subjects diagnosed with atopic dermatitis based on the Hanifin and Rajka diagnostic criteria
- •Subjects with chronic atopic dermatitis that has been present for at least 1 year before screening
- •Subjects with moderate to severe atopic dermatitis as indicated by:
- •EASI score ≥ 16 points at the time of screening and baseline (Day 1),
- •IGA score ≥ 3 points at the time of screening and baseline (Day 1), and
- •BSA affected by atopic dermatitis ≥ 10% at the time of screening and baseline (Day 1)
- •Subjects who have documented history of insufficient response to stable use of atopic dermatitis treatment within 24 weeks before screening, or inability to receive such treatment because of safety issues
- •Subjects who are willing to apply a stable dose of non-medicated topical moisturizer at least twice daily for at least 7 days before the baseline (Day 1) visit and the duration of the study
- •Women of childbearing potential who use appropriate contraceptive methods during this trial period
- •Subjects who have voluntarily agreed to participate in this trial in writing
Exclusion Criteria
- •Subjects with the following history of disease or surgery/procedure at screening
- •Malignancy or lympho-proliferative disease within 5 years before screening (except completely treated carcinoma in situ of the cervix, or completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin)
- •organ transplants
- •History of mental illness, drug or alcohol abuse within 2 years before screening, as per Investigator's opinion
- •Subjects with the following underlying disease at screening
- •Chronic active, acute infection or superficial skin infections requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals or antifungals;
- •Skin diseases, pigmentation, or extensive scarring other than atopic dermatitis that may affect the efficacy evaluations of the study
- •Renal dysfunction with serum creatinine level > 2.0 mg/dL at screening
- •Liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2.5 times the upper limit of the normal range (ULN) at the time of screening
- •Subjects with the history of using leukotriene receptor antagonists, systemic steroids, phototherapy, systemic immunosuppressants/modulators including janus kinase (JAK) inhibitors, and/or any other systemic therapy (not mentioned in Exclusion Criteria 6 and 8) to treat atopic dermatitis or symptoms of atopic dermatitis (approved or off-label use) within 4 weeks before baseline (Day 1)
- •Subjects with the history of using systemic or topical antihistamines, topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), or topical phosphodiesterase 4 (PDE4) inhibitors within 2 weeks before baseline (Day 1)
- •Allergen immunotherapy within 6 months before baseline (Day 1)
- •Subjects with the history of receipt of the following treatments before baseline (Day 1)
- •B cell-depleting agents including rituximab within 6 months
- •Other biologics including dupilumab within 5 half-lives (if known) or 12 weeks, whichever is longer
- •Subjects with regular use (more than two times per a week) of a tanning booth/parlor within 4 weeks before screening visit
- •Subjects with the history of a live (attenuated) vaccine injection within 12 weeks before baseline (Day 1) or the plan to inject a live (attenuated) vaccine within 24 weeks after randomization
- •Subjects who are deemed to require prohibited concomitant medications drug/therapy during the study period
- •Subjects with uncontrolled chronic disease that might require administration of oral corticosteroids such as uncontrolled and severe asthma
- •Pregnant/lactating women and men and women of childbearing potential who plan to become pregnant or who refuse to use appropriate contraceptive methods during the study period
- •Subjects with the history of receipt of any investigational products or devices from another clinical trial within 4 weeks or 5 half-lives (if known) pior to screening
- •Positive serology for hepatitis B or C, or for HIV
- •Subjects with prior use of FURESTEM-AD
- •Subjects with history of anaphylaxis
- •Subjects who are deemed to have difficulty in performing this study by the judgment of the Investigator and those with other medical findings that are unsuitable for participation in the study
Arms & Interventions
Furestem-AD Inj.
Experimental
Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).
After 12 weeks, Experimental group will receive placebo.
Intervention: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL (Biological)
Furestem-AD Inj.
Experimental
Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).
After 12 weeks, Experimental group will receive placebo.
Intervention: Placebo (Biological)
Placebo
Placebo Comparator
Placebo
baseline (0week) Placebo comparator group will receive placebo.
After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).
Intervention: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL (Biological)
Placebo
Placebo Comparator
Placebo
baseline (0week) Placebo comparator group will receive placebo.
After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).
Intervention: Placebo (Biological)
Outcomes
Primary Outcomes
EASI(Eczema Area and Severity Index)-50
Time Frame: 12 weeks
Ratio of subject whose Eczema Area and Severity Index (EASI) decreased over 50% as contrasted with baseline value
Secondary Outcomes
- BSA(Body Surface Area)(2,4,8,12 weeks)
- EASI(Eczema Area and Severity Index) index(2,4,8,12 weeks)
- SCORAD(SCORing Atopic Dermatitis)-50(2,4,8,12 weeks)
- Worst daily Pruritus NRS(Numerical Rating Scale)(2,4,8,12 weeks)
- IGA(Investigator's Global Assessment) Score(2,4,8,12 weeks)
- SCORAD(SCORing Atopic Dermatitis) index(2,4,8,12 weeks)
- POEM(Patient-Oriented Eczema Measure)(2,4,8,12 weeks)
- DLQI(Dermatology Life Quality Index)(2,4,8,12 weeks)
- EASI(Eczema Area and Severity Index)-75(2,4,8,12 weeks)
- EASI(Eczema Area and Severity Index)-50(2,4,8 weeks)
- Average daily Pruritus NRS(Numerical Rating Scale)(2,4,8,12 weeks)
- Rescue medicine(up to 12, 24 weeks)
- Worst daily Pruritus NRS(Numerical Rating Scale) - 4 points(2,4,8,12 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Efficacy and Safety Study of Probucol in Patients With Diabetic NephropathyDiabetic NephropathyNCT01726816Korea Otsuka Pharmaceutical Co., Ltd.126
Completed
Phase 2
Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic SurgeryAnalgesiaNCT04424251Haisco Pharmaceutical Group Co., Ltd.124
Completed
Phase 2
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 PatientsCOVID-19NCT04475107Shin Poong Pharmaceutical Co. Ltd.113
Terminated
Phase 2
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative ColitisColitis, UlcerativeNCT03893565GlaxoSmithKline104
Unknown
Phase 2
A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)Acquired Thrombotic Thrombocytopenic PurpuraNCT04021173Lee's Pharmaceutical Limited74